Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Status:
Terminated
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine if adjuvant therapy with axitinib will prevent or
delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high
risk patients.